Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that flutamide alone is more effective than finasteride for reducing hirsutism in women, and the combination of both drugs is not superior to flutamide alone.

This study found that finasteride 1 mg daily decreased 5alpha-dihydrotestosterone levels and improved hair growth in younger men with androgenetic alopecia, with higher initial hormone levels predicting better response.

Finasteride reduces inflammation and improves immune response after trauma by altering hormone levels.

In this study, low-dose finasteride (2.5 mg/day) significantly reduced hirsutism scores in women over 12 months without significant hormonal changes or serious side effects.

This study found that chronic exposure to finasteride did not significantly impact spermatogenesis in rats.

This study found that the gut microbiota composition in patients with post-finasteride syndrome differs significantly from healthy controls, with reduced diversity and specific microbial changes, suggesting a potential diagnostic marker and therapeutic target.

This article discusses the potential health risks associated with long-term use of finasteride and dutasteride for prostate and hair loss treatments, suggesting risks may include non-alcoholic fatty liver disease, insulin resistance, type 2 diabetes, and other metabolic issues.

This study found that finasteride significantly improved motor, EEG, and cellular changes in a rat model of thioacetamide-induced hepatic encephalopathy and prevented the development of hepatic coma.

This study found that adding low-dose dutasteride to ongoing finasteride treatment significantly improved hair density in a patient with androgenetic alopecia.

This study found that patients with bladder outlet obstruction and moderately enlarged prostates are likely to successfully discontinue the a-blocker doxazosin after 9 months of combination therapy with finasteride.

This study determined the molecular structure of finasteride and its related crystalline forms, highlighting different hydrogen-bond interactions and structural configurations in various crystalline complexes.

This study comprehensively compared different crystalline forms of finasteride, including the new finasteride DMF solvate hemihydrate, to better understand their structural characteristics and intermolecular interactions.

This study found that the less common CAG-rs4045402 and GGN-rs3138869 polymorphisms were more frequent in patients with post-finasteride syndrome and androgenetic alopecia, suggesting a genetic predisposition to AGA development.

This study suggests that genetic variants in the androgen receptor gene may predict which postmenopausal women with hair loss respond to finasteride therapy.

This study developed a pharmacokinetic/pharmacodynamic model for finasteride, concluding that finasteride's nonlinear pharmacokinetics are likely due to its saturable binding to 5alphaR2.

This review discusses post-finasteride syndrome, characterized by persistent symptoms despite discontinuation, and concludes that its existence cannot be confirmed; individualized assessment is advisable for those with a history of depression, sexual dysfunction, or infertility.

This study found that finasteride effectively prevented testosterone-induced kidney stone formation in renal tubular cells by reducing COM crystal adhesion and crystallization.

This meta-analysis found that treating male androgenetic alopecia with 5α-reductase inhibitors increases the risk of sexual dysfunction, with a statistically significant risk for finasteride but not for dutasteride.

This study found that the optimized finasteride-loaded lyophilized tablets using a self-nanoemulsifying drug delivery system improved bioavailability in human volunteers compared to the marketed finasteride product.

This study found that finasteride significantly reduced levodopa-induced dyskinesia in both male and female rats without diminishing l-DOPA's motor benefits, indicating potential for clinical trials in Parkinson's patients.

This study found that finasteride treatment significantly improved visual acuity, reduced central macular thickness, and decreased subretinal fluid presence in patients with central serous chorioretinopathy.

Method accurately measures finasteride in tablets using finasteride-BSA interaction.

This study found that invasomes enhanced the iontophoretic transdermal delivery of finasteride in rabbits, increasing AUC and T1/2 compared to oral suspension.

This case report describes a 40-year-old man whose secondary infertility, observed after prolonged finasteride use for hair loss, resolved following discontinuation of the drug, resulting in a live birth.

Finasteride boosts morphine's pain relief, stops tolerance, and reduces withdrawal in rats.

This study developed and validated a reliable method to measure finasteride levels in human plasma, which was successfully used to assess its pharmacokinetics after a 5 mg dose in healthy volunteers.

In this study, finasteride significantly improved hair growth and patient satisfaction in men with male pattern hair loss compared to placebo, with no drug-related adverse events reported.

Finasteride helps treat hair loss by blocking enzyme activity.

This study describes a case where finasteride treatment for benign prostatic hypertrophy was associated with gynecomastia in a 62-year-old man, which resolved after the drug was discontinued.

This study found that finasteride significantly reduced dihydrotestosterone levels but did not provide clear evidence of impaired libido or erectile function compared to placebo in men.